natgillin/translations-raw huggingface dataset:
Before using your NutropinAq Pen, please read the following instructions carefully. 
Pred uporabo injekcijskega peresnika NutropinAq Pen natančno preberite navodilo.
How to use NutropinAq 
Kako uporabljati zdravilo NutropinAq
Q: Where should I store my NutropinAq Pen? 
V: Kje naj shranjujem injekcijski peresnik NutropinAq Pen?
It is recommended that NutropinAq be administered using sterile, disposable needles. 
Zdravilo NutropinAq je priporočljivo aplicirati s sterilnimi injekcijskimi iglami za enkratno uporabo.
Growth rate increased significantly from 3.6-4.1 cm/year at baseline to 6.7-8.1 cm/year at Month 12, 6.7-6.8 cm/year at Month 24 and 4.5-5.1 cm/year at Month 48. 
12. mesecu, 6,7-6,8 cm/leto v 24. mesecu in 4,5-5,1 cm/leto v 48. mesecu.
Uncommon: Tachycardia 
Občasni: tahikardija
Injection sites include the upper arms, abdomen, and upper thighs. 
Mesta injiciranja so lahko nadlakti, trebuh in zgornji del stegen.
However, growth hormone treatment has not been shown to increase the incidence or severity of scoliosis. 
Čeprav zdravljenje z rastnim hormonom ni pokazalo zvečanja incidence ali poslabšanja skolioze, je potrebno med zdravljenjem spremljati znake skolioze.
Rare: Abdominal pain, diarrhoea, nausea, vomiting 
Redki: abdominalna bolečina, driska, navzea, bruhanje
Clinical efficacy and safety 
Klinična učinkovitost in varnost Zaostanek v rasti pri otrocih
Slide the needle in to pick it up and push the cap completely down over the needle. 
Potisnite iglo vanj, da ga boste dvignili, in porinite pokrovček do konca prek igle.
Uncommon: Injection site haemorrhage, injection site atrophy, injection site mass, hypertrophy 
Občasni: krvavitev na mestu injiciranja, atrofija na mestu injiciranja, zatrdlina na mestu injiciranja, hipertrofija
Patients with pre-existing hypothyroidism should be treated prior to the start of NutropinAq therapy. 
Bolnike s hipotiroidizmom je treba ustrezno zdraviti pred uvedbo zdravljenja z zdravilom NutropinAq.
Talk to you doctor or pharmacist before using NutropinAq. 
Pred začetkom uporabe zdravila NutropinAq se posvetujte z zdravnikom ali farmacevtom.
A: Your doctor or nurse will advise you what to do for the last dose in the cartridge. 
O: Zdravnik ali medicinska sestra vas bosta seznanila s postopkom za zadnji odmerek iz vložka.
Prepare the injection site by wiping with an antiseptic impregnated swab. 
Pripravite mesto injiciranja, tako da ga obrišete z zložencem, prepojenim z antiseptikom.
Up to 0.05 mg/kg bodyweight injected each day under the skin (subcutaneous injection). 
Do 0,05 mg/kg telesne mase, ki se ga vsak dan injicira pod kožo (subkutana injekcija).
Q: What should I do if I drop my NutropinAq Pen? 
V: Kaj naj storim, če mi injekcijski peresnik NutropinAq Pen pade?
Put a plaster on the injection site if you wish. 
Če želite, lahko injekcijsko mesto pokrijete z obližem.
Remove the green pen cap and unscrew the cartridge holder from the pen. 
Odstranite zeleni pokrovček injekcijskega peresnika in z injekcijskega peresnika odvijte držalo vložka.
The solution in the cartridge is stable for up to 28 days after first use when stored at 2 - 8°C. 
Vsebina vložka je stabilna 28 dni po prvi uporabi, če je vložek shranjen pri temperaturi 2 °C - 8 °C.
NutropinAq is essentially “sodium free” 
Zdravilo NutropinAq je v bistvu “brez natrija”.
Uncommon: Abdominal pain, vomiting, nausea, flatulence 
Občasni: abdominalna bolečina, bruhanje, navzea, flatulenca
For patients with diabetes mellitus, the dose of insulin may need adjustment after NutropinAq therapy is initiated. 
Pri bolnikih s sladkorno boleznijo utegne biti po uvedbi zdravljenja z zdravilom NutropinAq potrebna prilagoditev odmerka insulina.
There have been reports of sleep apnoea and sudden death after initiating therapy with growth hormone in paediatric patients with Prader-Willi syndrome who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnoea, or unidentified respiratory infection. 
Pri pediatričnih bolnikih s Prader-Willijevim sindromom, ki so imeli enega ali več od naslednjih rizičnih dejavnikov: prekomerno telesno maso, anamnezo obstrukcije zgornjih dihalnih poti ali apneje v spanju, ali neprepoznano okužbo dihal, so po uvedbi zdravljenja z rastnim hormonom poročali o pojavu apneje v spanju in nenadne smrti.
Rapid involuntary movements of the eyes (nystagmus), swelling of the optic nerve in the eye (papilloedema), double vision (diplopia), headache, somnolence and vertigo. 
Hitri, nehotni gibi očesnih zrkel (nistagmus), oteklina papile vidnega živca (papiledem), dvojni vid (diplopia), glavobol, somnolenca in vrtoglavica.
Rare: Asthenia, face oedema, fatigue, irritability, pain, pyrexia, injection site reaction (haemorrhage, haematoma, atrophy, urticaria, pruritus, swelling, erythema) 
Občasni: periferni edem, edem, reakcija na mestu injiciranja (iritacija, bolečina) Redki: astenija, edem obraza, utrujenost, razdražljivost, bolečina, zvišana telesna temperatura, reakcija na mestu injiciranja (krvavitev, hematom, atrofija, urtikarija, srbenje, oteklina, rdečina)
Somatropin is not recommended during pregnancy and should be discontinued if pregnancy occurs. 
Somatropina ne uporabljajte med nosečnostjo.
Events of diabetes mellitus and hyperglycaemia were reported in the post-marketing surveillance survey (see section 4.4). 
Med spremljanjem zdravila v obdobju trženja so poročali tudi o primerih sladkorne bolezni in hiperglikemije (glejte poglavje 4.4).
In childhood cancer survivors, an increased risk of a second neoplasm has been reported in patients treated with somatropin after their first neoplasm. 
Pri osebah, ki so v otroštvu prebolele raka, in so se nato zdravile s somatropinom, so poročali o večjem tveganju, da zbolijo za drugim tumorjem.
A total of 117 patients were treated with somatropin; 36 received somatropin 0.125 mg/kg three times a week and 81 patients received 0.054 mg/kg somatropin daily. 
36 bolnic je prejemalo somatropin v odmerku 0,125 mg/kg trikrat na teden, 81 bolnic pa v odmerku 0,054 mg/kg na dan. Zdravljenje je v skupini, ki je somatropin prejemala trikrat na dan, v povprečju trajalo 4,7 let, v skupini, ki je somatropin prejemala dnevno, pa 4,6 let.
NutropinAq is intended for use only with the NutropinAq Pen. 
Zdravilo NutropinAq je namenjeno le za uporabo z injekcijskim peresnikom NutropinAq Pen.
NutropinAq 10 mg/2 ml (30 IU) solution for injection. 
NutropinAq 10 mg/2 ml (30 i.e.) raztopina za injiciranje
If this appears to be particularly troublesome, you should discuss it with your doctor. 
Če ti neželeni učinki postanejo moteči, se posvetujte s svojim zdravnikom.
Physicians and parents should be alert to the development of a limp or complaints of hip or knee pain in patients treated with NutropinAq. 
Pri bolnikih, ki se zdravijo z zdravilom NutropinAq, morajo biti zdravniki in starši pozorni na pojav šepanja ali bolečin v kolčnem ali kolenskem sklepu.
The most common adverse events (AEs) observed in the pivotal studies were infection, headache, otitis media, fever, pharyngitis, rhinitis and gastroenteritis and vomiting. 
Najpogostejši neželeni učinki v ključnih študijah so bile okužba, glavobol, vnetje srednjega ušesa, zvišana telesna temperatura, faringitis, rinitis, gastroenteritis in bruhanje.
You should consult your doctor regularly as you may need adjustment of your glucocorticoid dose. 
Zdravnik bo morda moral prilagoditi odmerek glukokortikoida.
Uncommon: Exfoliative dermatitis, skin atrophy, skin hypertrophy, hirsutism, lipodystrophy, urticaria 
Občasni: eksfoliativni dermatitis, atrofija kože, hipertrofija kože, poraščenost moškega tipa pri ženskah, lipodistrofija, urtikarija
Neoplasm 
Dojenje
NutropinAq is supplied as a multi-dose solution. 
Zdravilo NutropinAq je na voljo v obliki večodmerne raztopine.
Respiratory thoracic and mediastinal disorders 
Bolezni dihal, prsnega koša in mediastinalnega prostora
• if you have a replacement therapy with glucocorticoids it may reduce the effect of NutropinAq on growth. 
Glukokortikoidi lahko zmanjšajo učinek zdravila NutropinAq na rast.
Slipped capital femoral epiphyses and aseptic necrosis of the femoral head may be seen in children with advanced renal osteodystrophy and in growth hormone deficiency, and it is uncertain whether these problems are affected by GH therapy. 
Pri otrocih z napredovalo ledvično osteodistrofijo in pomanjkanjem rastnega hormona se lahko pojavi zdrs epifize glavice stegnenice in aseptična nekroza glavice stegnenice, vendar pa vpliv zdravljenja z rastnim hormonom nanju ni pojasnjen.
However, no somatropin accumulation has been reported in children with chronic renal failure or end-stage renal disease dosed with current regimens. 
Vendar pri otrocih s kronično odpovedjo ledvic ali končnim stadijem ledvične bolezni, ki so dobivali odmerke po trenutnih shemah, niso opažali kopičenja somatropina.
• Avoid touching the cartridge rubber seal at all times. 
• Ne dotikajte se gumijaste zapore vložka.
Remove the paper seal from a new needle assembly and screw it onto the cartridge holder. 
Odstranite papirnato zaščitno nalepko s kompleta z novo iglo in iglo privijte na držalo vložka.
These events can be avoided by correct injection technique and rotation of injection sites. 
Pojav teh neželenih učinkov se lahko prepreči s pravilno tehniko injiciranja in rednim menjavanjem mest injiciranja.
What NutropinAq contains 
Kaj vsebuje zdravilo NutropinAq
Holding the pen with the needle pointing upward, gently tap the cartridge holder to move any air bubbles to the top. 
Držite injekcijski peresnik tako, da bo igla obrnjena navzgor in previdno potrkajte ob držalo vložka, da se bodo morebitni mehurčki dvignili na vrh.
Although rare, pancreatitis should be considered in somatropintreated children who develop abdominal pain. 
Primeri so sicer redki, vendar pa je pri otroku, ki se zdravi s somatropinom, v primeru pojava bolečine v trebuhu treba pomisliti na vnetje trebušne slinavke.
Hypothyroidism may develop during treatment with NutropinAq and untreated hypothyroidism may prevent optimal response to NutropinAq. 
Nezdravljeni hipotiroidizem lahko prepreči optimalen odziv na zdravilo NutropinAq.
Caution should be exercised while breast-feeding during treatment with NutropinAq. 
Med zdravljenjem z zdravilom NutropinAq je potrebna previdnost pri dojenju.
6 cartridges containing 2 ml solution for injection 
6 vložkov z 2 ml raztopine za injiciranje
Pancreatitis in children 
Vnetje trebušne slinavke pri otrocih
Protein metabolism 
Presnova beljakovin
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS {CARTRIDGE} 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
Set the required dose by turning the black dose knob. 
S sukanjem črnega odmernega gumba nastavite potrebni odmerek.
Your doctor or nurse will advise you regarding pen storage. 
Zdravnik ali medicinska sestra vam bosta povedala vse potrebno o shranjevanju injekcijskega peresnika.
3 cartridges containing 2 ml solution for injection 
3 vložki z 2 ml raztopine za injiciranje
NutropinAq reduces insulin sensitivity; glucose tolerance impairment was reported in both the pivotal and supportive clinical trials and the post-marketing surveillance survey. 
O moteni toleranci za glukozo so poročali tako v ključnih kot podpornih kliničnih preskušanjih in med spremljanjem zdravila v obdobju trženja.
You should stop taking NutropinAq if you are pregnant. 
Med nosečnostjo zdravila NutropinAq ne smete uporabljati.
<2D barcode carrying the unique identifier included> 
EDINSTVENA OZNAKA - DVODIMENZIONALNA ČRTNA KODA Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
• Your doctor should monitor you for high blood sugar levels (hyperglycemia) during treatment with NutropinAq. 
Zdravnik bo med zdravljenjem z zdravilom NutropinAq spremljal znake visoke vrednosti krvnega sladkorja.
Insert cartridge into the cartridge holder, then screw the cartridge holder back onto the pen. 
Vstavite vložek v držalo vložka in držalo vložka privijte nazaj na injekcijski peresnik.
If your hypothyroidism is not treated, it could stop NutropinAq from working. 
Nezdravljeni hipotiroidizem lahko prepreči delovanje zdravila NutropinAq.
One ml contains 5 mg of somatropin One cartridge contains 10 mg (30 IU) of somatropin 
En vložek vsebuje 10 mg (30 i.e.) somatropina.
Either of the NutropinAq cartridge designs can be used with either of the NutropinAq Pen designs. 
NutropinAq vložki v obeh zunanjih podobah se lahko uporabljajo z injekcijskim peresnikom NutropinAq Pen v obeh zunanjih podobah.
Somatropin must not be used when there is any evidence of activity of a tumour. 
Če obstajajo dokazi o aktivnosti tumorja, se somatropina ne sme uporabljati.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS {BLISTER} 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI DVOJNEM TRAKU
Patients received an s.c. dose of 0.125 mg/kg three times a week or 0.054 mg/kg/day, both regimens giving a cumulative weekly dose of approximately 0.375 mg/kg. 
Obe shemi zagotavljata kumulativni tedenski odmerek približno 0,375 mg/kg.
When travelling, place your pen case in a cooler. 
Na potovanju hranite škatlico z injekcijskim peresnikom v hladilni posodi.
In children, NutropinAq is used: 
Pri otrocih zdravilo NutropinAq uporabljamo:
Use a cooler to store your NutropinAq Pen when travelling. 
Med potovanjem hranite injekcijski peresnik NutropinAq Pen v hladilni posodi.
A: The battery in your NutropinAq Pen is losing its charge. 
O: Baterija v injekcijskem peresniku izgublja napetost.
Oedema was reported as common in children. 
Pri otrocih so o pojavu edema poročali kot o pogostem neželenem učinku.
EXP: {date} After first opening, use before 28 days at 2°C - 8°C. 
Uporabno do: {datum} Po prvem odprtju shranjujte v hladilniku (2 °C - 8 °C) in porabite v 28 dneh.
Intracranial hypertension with papilloedema, visual changes, headache, nausea and/or vomiting has been reported in a small number of patients treated with somatropin. 
Pri majhnem številu bolnikov, zdravljenih s somatropinom, so poročali o intrakranialni hipertenziji s papiledemom, spremembami vida, glavobolom, navzeo in/ali bruhanjem.
Leukaemia has been reported in a small number of growth hormone deficient patients treated with growth hormone. 
Pri manjšem številu bolnikov s pomanjkanjem rastnega hormona, ki so se zdravili z rastnim hormonom, so poročali o pojavu levkemije.
Uncommon: Slipped capital femoral epiphysis, scoliosis progression, arthralgia Rare: Bone development abnormal, osteochondrosis, muscular weakness, pain in extremity 
Redki: nenormalen razvoj kosti, osteohondroza, mišična oslabelost, bolečina v okončinah
Keep the blister in the outer carton. 
Pretisni omot shranjujte v škatli.
Freezing will damage the pen and medicine. 
O: Ne. Zamrzovanje okvari injekcijski peresnik in zdravilo.
The most commonly reported AEs were flu syndrome, infection, headache, pharyngitis, rhinitis and otitis media. 
Najpogosteje so poročali o naslednjih neželenih učinkih: gripi podobnemu sindromu, okužbi, glavobolu, faringitisu, rinitisu in vnetju srednjega ušesa.
Funduscopic examination is recommended at the initiation and periodically during the course of treatment. 
Na začetku in redno med zdravljenjem so priporočljivi pregledi očesnega ozadja.
Localised loss/gain of fat from the skin (lipodystrophy, injection site atrophy/hypertrophy) Enlarged adenoids with similar symptoms as enlarged tonsils (see rare). 
Povečanje adenoidnega tkiva s podobnimi simptomi, kot pri povečanju tonzil (glejte redki).
This was accompanied by a significant increase in height SDS from -0.1 to 0.5 at baseline to 0.0 to 0.7 at Month 12 and 1.6 to 1.7 at Month 48. 
To je spremljalo pomembno povečanje vrednosti SDS telesne višine od -0,1 do 0,5 v izhodišču do vrednosti od 0,0 do
Always refer to the LCD (Liquid Crystal Display), not audible clicks, for setting an injection of NutropinAq. 
Za nastavitev odmerka zdravila NutropinAq se ne smete zanašati na slišne klike, ampak morate vedno uporabiti prikazovalnik LCD (prikazovalnik s tekočimi kristali).
Gently swirl. 
nadlaket trebuh stegno
• Phamacovigilance System 
• Sistem farmakovigilance
No effect on ability to drive or use machines has been noticed while using NutropinAq. 
Vplivov zdravila NutropinAq na sposobnost upravljanja vozil in strojev niso opazili.
Feeling of weakness (asthenia) and increased muscle tension (hypertonia) 
Pomanjkanje ali izguba moči ali energije (astenija) in zvečan tonus mišic (hipertonija).
1 cartridge containing 2 ml solution for injection 
1 vložek z 2 ml raztopine za injiciranje
Two pivotal, multicentre, controlled studies have been conducted in patients with growth failure associated with chronic renal insufficiency (CRI). 
Pri bolnikih z zaostankom v rasti, povezanim s kronično ledvično insuficienco, sta bili izvedeni dve ključni, multicentrični nadzorovani študiji.
Use a damp cloth to wipe away dirt. 
Umazanijo odstranite z vlažno krpico.
The site of injection should be changed. 
Raztopino za injiciranje je treba aplicirati subkutano vsak dan. Mesto injiciranja je treba menjati.
Reactions observed from the post marketing environment 
Neželeni učinki, opaženi med spremljanjem zdravila po prihodu na trg
Read all the instructions for use carefully (on the reverse) before you start using NutropinAq Pen. 
Preden začnete uporabljati injekcijski peresnik NutropinAq Pen, natančno preberite navodila za njegovo uporabo (na hrbtni strani navodila).
Uncommon: Neoplasm malignant, neoplasm benign 
Občasni: maligni tumor, benigni tumor
How to store NutropinAq 
Shranjevanje zdravila NutropinAq
Ask advice from you doctor before you stop using NutropinAq. 
Preden prenehate uporabljati zdravilo NutropinAq, se posvetujte s svojim zdravnikom.
Injection site reactions such as haemorrhage, atrophy, urticaria and pruritus were reported in the pivotal and supportive clinical trials and/or the post-marketing surveillance survey. 
V ključnih in podpornih kliničnih preskušanjih in/ali med spremljanjem zdravila v obdobju trženja so poročali o reakcijah na mestu injiciranja, kot so krvavitev, atrofija, urtikarija in srbenje.
Attach the pen cap and return it to its case with the black dose knob pressed in. You should always store the pen in a refrigerator. 
Namestite pokrovček injekcijskega peresnika in ga, s črnim odmernim gumbom potisnjenim navznoter, položite nazaj v škatlico.
Sodium Citrate Dihydrate Citric Acid, Anhydrous Water for Injections 
6.1 Seznam pomožnih snovi natrijev klorid tekoči fenol polisorbat 20 natrijev citrat dihidrat brezvodna citronska kislina voda za injekcije
The average treatment time was 4.7 years in the somatropin three times a week group and 4.6 years in the somatropin daily group. 
Zdravljenje je v povprečju trajalo 3,2 in 4,6 let, skupna izpostavljenost pa je znašala 542 bolnikov-let.
Patients should have periodic thyroid function tests and should be treated with thyroid hormone when required. 
Pri bolnikih je treba redno opravljati preiskave delovanja ščitnice in po potrebi uvesti ustrezno zdravljenje.
- Keep this leaflet. 
Previdno vrtite.
A: No. 
NN: {številka}
Therefore, patients should have periodic thyroid function tests and should be treated with thyroid hormone when indicated. 
Zato morajo bolniki redno opravljati preiskave delovanja ščitnice.
Drink straight away. 
Takoj popijte.
The effect was significant from the first year. 
Učinek je bil signifikanten od prvega leta naprej.
The cause of this finding is unknown. 
Vzrok tovrstnih izsledkov ni znan.
The risk of fractures is increased with the number of risk factors. 
Tveganje za zlome se povečuje s številom dejavnikov tveganja.
Just carry on with the next dose at the normal time. 
Preprosto nadaljujte z naslednjim odmerkom ob običajnem času.
Add water; 
Dolijte vodo.
If this is not possible, it is acceptable to take the two medicines at the same time. 
Kadar to ni mogoče, je sočasno jemanje obeh zdravil sprejemljivo.
Additional risk minimisation measures 
Dodatni ukrepi za zmanjševanje tveganja
Interaction with laboratory test 
Interakcije z laboratorijskimi preiskavami
The newly formed bone is of normal quality. 
Novonastala kost je normalne kakovosti.
System Organ Class (SOC) Frequency category 
Razred organskega sistema (SOC - System Organ Class) Kategorija pogostnosti
6.3 Shelf life - 3 years. 
6.3 Rok uporabnosti - 3 leta.
Stir until the granules are evenly dispersed in the water. 
Mešajte, dokler se zrnca enakomerno ne porazdelijo v vodi.
Strontium has a volume of distribution of about 1 l/kg. 
Stroncij ima volumen porazdelitve približno 1 l/kg.
Your doctor will tell you how long you should continue to take OSSEOR. 
Zdravnik vam bo povedal, koliko časa morate jemati OSSEOR.
• When to seek urgent medical advice. 
• kdaj je potrebno poiskati nujno zdravniško pomoč,
Early withdrawal is associated with a better prognosis. 
Zgodnja prekinitev jemanja zdravila je povezana z boljšo prognozo.
Your doctor will not prescribe OSSEOR for you if you are at particular risk. 
Vaš zdravnik vam ne bo predpisal zdravila OSSEOR, če ste še posebej ogroženi.
You can take OSSEOR again when you have finished taking these antibiotics. 
OSSEOR lahko ponovno začnete jemati, ko prenehate z jemanjem tovrstnih antibiotikov.
• Importance of regularly monitoring cardiovascular risk. 
• pomen rednega spremljanja tveganja za srčno-žilne dogodke.
Patients should be advised of the signs and symptoms and monitored closely for skin reactions. 
Bolnike moramo obvestiti o znakih in simptomih ter pozorno spremljati njihove kožne reakcije.
This is especially common in women after the menopause. 
Zlasti pogosto se to dogaja pri ženskah v obdobju po menopavzi.
Many people with osteoporosis have no symptoms and you may not even know that you have it. 
Mnogi bolniki z osteoporozo nimajo simptomov in mogoče je, da sploh ne veste, da bolezen že imate.
The effective half-life of strontium is about 60 hours. 
Efektivna razpolovna doba stroncija je približno 60 ur.
OSSEOR has been studied in clinical trials involving nearly 8,000 participants. 
OSSEOR so proučevali v kliničnih študijah, ki so zajele skoraj 8000 bolnikov.
Your body is constantly breaking down old bone and making new bone tissue. 
Telo neprestano razgrajuje staro kost in tvori novo kostno tkivo.
In rats, these effects were reversible 8 weeks after cessation of treatment. 
Pri podganah so ti učinki izginili 8 tednov po prekinitvi zdravljenja.
Children and adolescents OSSEOR is not intended for use in children and adolescents (below the age of 18). 
OSSEOR ni namenjen otrokom in mladostnikom (mlajšim od 18 let).
After approval of the protocol, annual reports from this study shall be provided within the PSUR until submission of the final study report, which is due by December 2017. 
Po odobritvi protokola je potrebno letna poročila iz te študije predložiti skupaj s periodičnim poročilom o varnosti zdravila (PSUR) pred predložitvijo končnega poročila o študiji, ki je predvidena decembra 2017.
OSSEOR with food and drink: 
Zdravilo OSSEOR skupaj s hrano in pijačo
All patients received daily supplemental calcium (1000 mg) and vitamin D (800 UI). 
Vsi bolniki so dnevno prejemali dodatek kalcija (1000 mg) in vitamina D (800 i.e.).
Mean age was 75 years at inclusion and 23% of the patients enrolled were 80 to 100 years of age. 
Srednja starost ob vključitvi je bila 75 let in 23 % vključenih bolnic je bilo starih od 80 do 100 let.
Boxes containing 7, 14, 28, 56, 84 or 100 sachets. 
Škatle vsebujejo 7, 14, 28, 56, 84 ali 100 vrečk.
Date of latest renewal: 21/09/2009 
Datum prve odobritve: 21/09/2004 Datum zadnjega podaljšanja: 21/09/2009
INFORMATION IN BRAILLE OSSEOR 2 g 
PODATKI V BRAILLOVI PISAVI OSSEOR 2 g
How OSSEOR works 
Kako OSSEOR deluje
The rash may progress to widespread blistering or peeling of the skin. 
Izpuščaj lahko napreduje do razširjenih mehurjev ali luščenja kože.
Heart attack may occur commonly in patients at high risk for heart disease. 
Srčni infarkt lahko pogosto nastopi pri bolnikih z visokim tveganjem za bolezen srca.
Strontium ranelate does not present a risk for the environment. 
Stroncijev ranelat ne predstavlja tveganja za okolje.